PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Dantes, Z.* ; Yen, H.Y.* ; Pfarr, N.* ; Winter, C.* ; Steiger, K.* ; Muckenhuber, A.* ; Hennig, A.* ; Lange, S.* ; Engleitner, T.* ; Öllinger, R.* ; Maresch, R.* ; Orben, F.* ; Heid, I.* ; Kaissis, G.* ; Shi, K.* ; Topping, G.* ; Stögbauer, F.* ; Wirth, M.* ; Peschke, K.* ; Papargyriou, A.* ; Rezaee-Oghazi, M.* ; Feldmann, K.* ; Schäfer, A.P.* ; Ranjan, R.* ; Lubeseder-Martellato, C.* ; Stange, D.E.* ; Welsch, T.* ; Martignoni, M.* ; Ceyhan, G.O.* ; Friess, H.* ; Herner, A.* ; Liotta, L.A.* ; Treiber, M.* ; von Figura, G.* ; Abdelhafez, M.* ; Klare, P.* ; Schlag, C.* ; Algül, H.* ; Siveke, J.* ; Braren, R.* ; Weirich, G.* ; Weichert, W.* ; Saur, D.* ; Rad, R.* ; Schmid, R.M.* ; Schneider, G.* ; Reichert, M.*

Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology.

JCI insight 5:e137809 (2020)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
One of the major challenges in using pancreatic cancer patient-derived organoids (PDOs) in precision oncology is the time from biopsy to functional characterization. This is particularly true for endoscopic ultrasound-guided fine-needle aspiration biopsies, typically resulting in specimens with limited tumor cell yield. Here, we tested conditioned media of individual PDOs for cell-free DNA to detect driver mutations already early on during the expansion process to accelerate the genetic characterization of PDOs as well as subsequent functional testing. Importantly, genetic alterations detected in the PDO supernatant, collected as early as 72 hours after biopsy, recapitulate the mutational profile of the primary tumor, indicating suitability of this approach to subject PDOs to drug testing in a reduced time frame. In addition, we demonstrated that this workflow was practicable, even in patients for whom the amount of tumor material was not sufficient for molecular characterization by established means. Together, our findings demonstrate that generating PDOs from very limited biopsy material permits molecular profiling and drug testing. With our approach, this can be achieved in a rapid and feasible fashion with broad implications in clinical practice.
Impact Factor
Scopus SNIP
Altmetric
6.205
1.515
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Gastroenterology ; Oncology ; Translation
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 2379-3708
e-ISSN 2379-3708
Zeitschrift JCI insight
Quellenangaben Band: 5, Heft: 15, Seiten: , Artikelnummer: e137809 Supplement: ,
Verlag Clarivate
Verlagsort Ann Arbor, Michigan
Begutachtungsstatus Peer reviewed
Institut(e) Helmholtz Artifical Intelligence Cooperation Unit (HAICU)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-530014-001
DOI 10.1172/jci.insight.137809
PubMed ID 32614802
Erfassungsdatum 2022-09-13
[➜Korrektur melden]